ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Clinical trials for ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC) explained in plain language.
Never miss a new study
Get alerted when new ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC) trials appear
Sign up with your email to follow new studies for ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New gel shows promise for rosacea redness in small study
Symptom relief CompletedThis study tested a gel containing brimonidine to see if it can reduce persistent facial redness in people with rosacea. In the first part, 45 adults applied the gel to one side of their face and a placebo to the other, measuring redness after a few hours. In the second part, the…
Matched conditions: ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Phase: PHASE4 • Sponsor: Istanbul Training and Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Can a nerve pain drug calm rosacea Flare-Ups?
Symptom relief CompletedThis study tested whether gabapentin, a drug usually used for nerve pain, can reduce facial flushing and redness in people with rosacea. Fifty adults with rosacea took different doses of gabapentin or standard treatment for up to 12 weeks. Researchers measured changes in redness …
Matched conditions: ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Phase: PHASE1 • Sponsor: First Affiliated Hospital of Chongqing Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC